Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

First-line Therapy in Metastatic PDAC (FOOTPATH)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03487016
Recruitment Status : Recruiting
First Posted : April 3, 2018
Last Update Posted : February 18, 2019
Sponsor:
Information provided by (Responsible Party):
PD Dr. med. Volker Heinemann, Ludwig-Maximilians - University of Munich

Tracking Information
First Submitted Date  ICMJE March 4, 2018
First Posted Date  ICMJE April 3, 2018
Last Update Posted Date February 18, 2019
Actual Study Start Date  ICMJE February 15, 2019
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
Progression-free survival [ Time Frame: 60 months ]
PFS
Original Primary Outcome Measures  ICMJE Same as current
Change History
Current Secondary Outcome Measures  ICMJE
 (submitted: April 2, 2018)
  • Overall survival [ Time Frame: 60 months ]
    OS
  • Objective response rate [ Time Frame: 60 months ]
    ORR
  • Disease control rate [ Time Frame: 60 months ]
    DCR
  • Duration of study treatment [ Time Frame: 60 months ]
    Time on therapy
  • Type, incidence, causal relationship and severity of adverse events according to NCI CTCAE version 4.03 [ Time Frame: 60 months ]
    Safety
  • Efficacy of second-line chemotherapy [ Time Frame: 60 months ]
    Second Line Therapy I Assessed through progression free survival after initiation of second-line therapy.
  • Choice of second-line chemotherapy [ Time Frame: 60 months ]
    Second Line Therapy II Type of second line therapy will be recorded in a descriptive manner based on available health records.
  • Duration of second-line chemotherapy [ Time Frame: 60 months ]
    Second Line Therapy III
  • Quality of life as assessed by EORTC-QLQ-C30 [ Time Frame: 60 months ]
    Quality of life will be assessed by the European Organisation for Research and Treatment of Cancer (EORTC) core Quality of Life Questionnaire (QLQ). The QLQ-C30 is composed of both multi-item scales and single-item measures. These include five functional scales, three symptom scales, a global health status / QoL scale, and six single items. Each of the multi-item scales includes a different set of items - no item occurs in more than one scale. All of the scales ands ingle-item measures range in score from 0 to 100. A high scale score represents a higher response level. Thus a high score for a functional scale represents a high / healthy level of functioning, a high score for the global health status / QoL represents a high QoL, but a high score for a symptom scale / item represents a high level of symptomatology / problems. Scoring is done based on the following document: EORTC QLQ-C30 Scoring Manual
Original Secondary Outcome Measures  ICMJE Same as current
Current Other Pre-specified Outcome Measures
 (submitted: April 2, 2018)
  • Molecular subtypes of pancreatic cancer as predictors of response to chemotherapy [ Time Frame: 60 months ]
    Translational 1
  • Evaluation of radiologic early tumor shrinkage [ Time Frame: 60 months ]
    ETS will be assessed after 8 weeks of treatment. Early tumour shrinkage (ETS) will be analysed based on sum of longest diameters of target lesions (SLD). Shrinkage will be classified as ETS (shrinkage by ≥20%), mETS (minor shrinkage by 0% - <20%), mPD (minor progression by >0% - <20%), PD (progression by ≥20% or new lesion). In all caculations, shrinkage will be expressed as a positive denominator.
  • Evaluation of radiologic depth of response [ Time Frame: 60 months ]
    Radiologic depth of response is (DpR) is defined as the percentage of tumour shrinkage, based on sum of longest diameters of target lesions (SLD) observed at the lowest point (nadir) compared with baseline imaging. Tumour shrinkage (TS) will be classified as: (shrinkage by ≥20%), mTS (minor shrinkage by 0% - <20%), mPD (minor progression by >0% - <20%), PD (progression by ≥20% or new lesion). In all caculations, shrinkage will be expressed as a positive denominator.
  • Kinetics of circulating tumor DNA during first-line chemotherapy [ Time Frame: 60 months ]
    Translational 1 Circulating tumour DNA will be assessed through polymerase chain reaction based techniques and the concentration will be denominated as "ng/mL of plasma". Samples will be collected at the start of each cycle to allow for the detection of changing concentrations during first-line treatment.
Original Other Pre-specified Outcome Measures Same as current
 
Descriptive Information
Brief Title  ICMJE First-line Therapy in Metastatic PDAC
Official Title  ICMJE A Multicenter Randomized Phase II Study to Determine the Optimal First-line Chemotherapy Regimen in Patients With Metastatic Pancreatic Cancer
Brief Summary The overarching hypothesis of this trial is that the NAPOLI regimen and alternating cycles of NAPOLI and mFOLFOX6 (seq-NAPOLI-FOLFOX) are superior to the current standard of care gemcitabine/nab-paclitaxel. Furthermore, we propose that the NAPOLI regimen and seq-NAPOLI-FOLFOX display favourable safety profiles and allow for longer first line treatment and higher rate of transition into the second line setting.
Detailed Description

Pancreatic ductal adenocarcinoma (PDAC) remains an almost uniformly lethal disease. Although there has been significant progress in understanding of the underlying molecular biology of pancreatic cancer, this progress has not translated into substantially better outcome.

Alarmingly, the number of pancreatic cancer cases is constantly rising and pancreatic cancer will be the second most frequent cause of cancer related death by 2030.

Accordingly, novel therapeutic strategies for patients with pancreatic cancer are desperately needed.

Recently, the combination of gemcitabine and nab-paclitaxel proofed to be superior when compared to single agent gemcitabine (overall survival [OS] 8.7 months in the nab-paclitaxel/gemcitabine group versus 6.6 months in the gemcitabine group; hazard ratio for death, 0.72; 95% confidence interval [CI], 0.62 to 0.83; P<0.001). Consequently, this combination therapy is now regarded as a standard treatment option for patients with metastatic pancreatic cancer and should therefore serve as control for future clinical studies.

Furthermore, the combination of 5-fluorouracil (5-FU), irinotecan and oxaliplatin (FOLFIRINOX) was found to be more effective in the treatment of metastatic pancreatic cancer when compared to gemcitabine monotherapy (overall survival 11.1 month in the FOLFIRINOX group versus 6.8 months in the gemcitabine group - hazard ratio for death, 0.57; 95% confidence interval [CI], 0.45 to 0.73; P<0.001). However, this increased activity came at the cost of higher treatment-related side effects.

Recently, the NAPOLI-1 trial yielded promising results for the combination of liposomal irinotecan (nal-Iri) in combination with 5-FU/folinic acid (FA) in patients pretreated with a gemcitabine-based first-line regimen.

Finally, Phase II data show promising efficacy and favorable toxicity with conventional FOLFIRI.3 in the treatment of advanced pancreatic cancer.

Furthermore, studies in colorectal cancer demonstrated a comparable efficacy and favorable toxicity when comparing conventional FOLFOXIRI (+ bevacizumab) and sequential FOLFOXIRI (alternating FOLFOX and FOLFIRI) in combination with bevacizumab.

With these novel treatment options at hand it is imperative to define the optimal first-line treatment modality in order to allow for an optimized treatment sequence to ensure for maximal success with acceptable toxicity.

Study Type  ICMJE Interventional
Study Phase  ICMJE Phase 2
Study Design  ICMJE Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Condition  ICMJE Metastatic Pancreatic Cancer
Intervention  ICMJE
  • Drug: Gemcitabine
    Arm A
    Other Name: Gemzar
  • Drug: Nab-paclitaxel
    Arm A
    Other Name: Abraxane
  • Drug: 5-FU
    Arm B Arm C
    Other Name: 5-Fluoruracil
  • Drug: Irinotecan Liposomal Injection
    Arm B Arm C
    Other Name: Onivyde
  • Drug: Oxaliplatin
    Arm C
    Other Name: Trans-l-diaminocyclohexanoxalatoplatin
Study Arms  ICMJE
  • Active Comparator: A: Gemcitabine/nab-Paclitaxel (Standard)

    Nab-paclitaxel 125 mg/m2, i.v. infusion over about 30 minutes followed by Gemcitabine 1000 mg/m2 as a 30-minute i.v. infusion on D1, D8, D15 of a 28-day cycle.

    Treatment is given until disease progression or the occurrence of unacceptable toxicity.

    Interventions:
    • Drug: Gemcitabine
    • Drug: Nab-paclitaxel
  • Experimental: B: NAPOLI regimen

    On Day 1 of a 14-day cycle:

    Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

    Treatment is given until disease progression or the occurrence of unacceptable toxicity.

    Interventions:
    • Drug: 5-FU
    • Drug: Irinotecan Liposomal Injection
  • Experimental: C: seq-NAPOLI-FOLFOX

    The NAPOLI regimen and the mFOLFOX6 regimen are applied in an alternating fashion, starting with the NAPOLI regimen.

    NAPOLI:

    On Day 1 of a 14-day cycle:

    Liposomal irinotecan 80 mg/m2 i.v. over about 90 minutes followed by Folinic acid 400 mg/m2 i.v. over about 30 minutes followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

    mFOLFOX6:

    On Day 1 of a 14-day cycle:

    Oxaliplatin 85 mg/m2 as i.v. infusion over 2 to 6 hours according to local practice at trial site Folinic acid 400 mg/m2 as i.v. infusion; infusion duration according to local practice at trial site followed by 5-FU 2400 mg/m2 i.v. over about 46 h (pump)

    Treatment is given until disease progression or the occurrence of unacceptable toxicity.

    Interventions:
    • Drug: 5-FU
    • Drug: Irinotecan Liposomal Injection
    • Drug: Oxaliplatin
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status  ICMJE Recruiting
Estimated Enrollment  ICMJE
 (submitted: April 2, 2018)
270
Original Estimated Enrollment  ICMJE Same as current
Estimated Study Completion Date  ICMJE June 2023
Estimated Primary Completion Date June 2022   (Final data collection date for primary outcome measure)
Eligibility Criteria  ICMJE

Inclusion Criteria:

  • Adult patients ≥ 18 years of age and ≤ 75 years
  • Histologically (not cytologically) confirmed diagnosis of metastatic pancreatic ductal adenocarcinoma (PDAC) [Stage IV according to UICC TNM edition 8 of 201622: each T, each N, M1]
  • No option for surgical resection or radiation in curative intent
  • At least one unidimensionally measurable tumor lesion (according to RECIST 1.1)
  • ECOG performance status 0 - 1
  • Life expectancy at least 3 months
  • Adequate hepatic, renal and bone marrow function, defined as:
  • Absolute neutrophil count (ANC) ≥ 1.5 x 109/L
  • Haemoglobin ≥ 9 g/dL
  • Thrombocytes ≥ 100 x 109/L
  • Total bilirubin ≤ 1.5 x ULN. Patients with a biliary stent may be included provided that bilirubin level after stent insertion decreased to ≤ 1.5 x ULN and there is no cholangitis.
  • AST/GOT and/or ALT/GPT ≤ 2.5 x ULN or in case of liver metastasis ≤ 5 x ULN)
  • Serum creatinine within normal limits or creatinine clearance ≥ 60 mL/min/1.73 m2 as calculated by CKD-EPI formula for patients with serum creatinine levels above or below the institutional normal value.
  • Females of childbearing potential (FCBP) must have a negative highly sensitive serum pregnancy test within 7 days of the first administration of study treatment and they must agree to undergo a further pregnancy tests at monthly intervals and at the end of treatment visit and FCBP must either agree to use and be able to take highly effective contraceptive birth control methods (Pearl Index < 1) during the course of the study and for at least 1 month after last administration of study treatment. Complete sexual abstinence is acceptable as a highly effective contraceptive method only if the subject is refraining from heterosexual intercourse during the entire study treatment and at least one month after the discontinuation of study treatment and the reliability of sexual abstinence is in line with the preferred and usual lifestyle of the subject. A female subject following menarche is considered to be of childbearing potential unless she is naturally amenorrhoeic for ≥ 1 year without an alternative medical reason, or unless she is permanently sterile.
  • Males must agree to use condoms during the course of the trial and for at least 6 months after last administration of study drugs or practice complete abstinence from heterosexual intercourse.
  • Signed and dated informed consent before the start of any specific protocol procedures
  • Patient's legal capacity to consent to study participation

Exclusion Criteria:

  • Locally advanced PDAC without metastasis
  • Symptomatic/clinically significant ascites (expected indication for repeated paracentesis)
  • Known metastatic disease to the brain. Brain imaging is required in symptomatic patients to rule out brain metastases, but is not required in asymptomatic patients.
  • Previous palliative chemotherapy or other palliative systemic tumor therapy for metastatic disease of PDAC
  • Previous gemcitabine or 5-FU based treatment with exception of gemcitabine/fluoropyrimidine based treatment applied in the neoadjuvant or adjuvant setting (before/after potential curative R0 or R1 resection) and if the neoadjuvant/adjuvant chemotherapy was terminated at least 6 months before randomization
  • Previous radiotherapy of PDAC with exception of radiotherapy in the context of a neoadjuvant or adjuvant treatment setting that was terminated at least 6 months before randomization
  • Any major surgery within the last 4 weeks before randomization
  • Clinically significant decrease in performance status within 2 weeks of intended first administration of study medication (by medical history)
  • Severe tumor-related cachexia and/or known weight loss > 15% within one month before study enrollment
  • Pre-existing polyneuropathy ≥ grade 2 according to CTCAE version 4.03
  • Gastrointestinal disorders that might interfere with the absorption of the study drug and gastrointestinal disorders with diarrhoea as a major symptom (e.g. Crohn's disease, malabsorption), and chronic diarrhoea of any aetiology CTCAE version 4.03 grade ≥ 2
  • Any other severe concomitant disease or disorder, which could influence patient's ability to participate in the study and his/her safety during the study or interfere with interpretation of study results e.g. active infection, uncontrolled hypertension, clinically significant cardiovascular disease e.g. cerebrovascular accident (≤ 6 months before study start), myocardial infarction (≤ 6 months before study start), unstable angina, heart failure ≥ NYHA functional classification system grade 2, severe cardiac arrhythmia requiring medication, metabolic dysfunction, severe renal disorder.
  • Any other malignancies than PDAC within the last 5 years before study start, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer
  • Hypersensitivity to the study drugs or to any of the excipients or to compounds with similar chemical or biologic composition
  • Use of strong CYP3A4 inhibitors (CYP3A4 inhibitors have to be discontinued at least one week prior to start of study treatment).

Use or strong UGT1A1 inhibitors or strong CYP3A4 inducers unless there are no therapeutic alternatives.

  • Known glucuronidation deficiency (Gilbert's syndrome) (specific screening not required)
  • Known DPD deficiency (specific screening not required)
  • Requirement for concomitant antiviral treatment with sorivudine or brivudine
  • Continuing abuse of alcohol, drugs, or medical drugs
  • Pregnant or breast-feeding females or FCBPs unable to either perform highly effective contraceptive measures or practice complete abstinence from heterosexual intercourse
  • Current or recent (within 4 weeks prior to randomization) treatment with an investigational drug or participation in an investigational clinical trial
Sex/Gender  ICMJE
Sexes Eligible for Study: All
Ages  ICMJE 18 Years to 75 Years   (Adult, Older Adult)
Accepts Healthy Volunteers  ICMJE No
Contacts  ICMJE
Contact: Benedikt Westphalen, MD +49894400 ext 75257 cwestpha@med.lmu.de
Contact: Sandy Neumann +49894400 ext 75257 Sandy.Neumann@med.uni-muenchen.de
Listed Location Countries  ICMJE Germany
Removed Location Countries  
 
Administrative Information
NCT Number  ICMJE NCT03487016
Other Study ID Numbers  ICMJE 2017-003496-54
Has Data Monitoring Committee No
U.S. FDA-regulated Product
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
IPD Sharing Statement  ICMJE Not Provided
Responsible Party PD Dr. med. Volker Heinemann, Ludwig-Maximilians - University of Munich
Study Sponsor  ICMJE Ludwig-Maximilians - University of Munich
Collaborators  ICMJE Not Provided
Investigators  ICMJE
Principal Investigator: Volker Heinemann, MD LMU Munich
PRS Account Ludwig-Maximilians - University of Munich
Verification Date February 2019

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP